The proportion of patients using basal insulin, which initially was higher in the CKD group, did not change greatly after 12 months, although the dose of basal insulin was reduced, albeit non-significantly: 36.0 (22.0–50.0) IU/mL vs. 34.0 (22.0–48.0) IU/mL, median (IQR), in no/low CKD risk patients at baseline and 12 months respectively; 44.0 (29.0–61.0) IU/mL vs. 38.0 (24.7–60.0) IU/mL in CKD patients at baseline and 12 months, respectively. This evidence concerns the gene INS and chronic kidney disease.